	US 12,378,522 B2
	Cell therapy compositions and methods of use thereof
Edmund Sullivan, Bellingham, WA (US); and Theresa Westfall, Bellingham, WA (US)
Assigned to AURELIUS BIOTHERAPEUTICS, LLC, Bellingham, WA (US)
Filed by Aurelius Biotherapeutics, LLC, Bellingham, WA (US)
Filed on Apr. 10, 2023, as Appl. No. 18/132,713.
Application 18/132,713 is a continuation of application No. 16/320,729, granted, now 11,648,265, issued on May 16, 2023, previously published as PCT/US2017/046354, filed on Aug. 10, 2017.
Claims priority of provisional application 62/373,243, filed on Aug. 10, 2016.
Prior Publication US 2023/0372392 A1, Nov. 23, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/0784 (2010.01); A61K 31/475 (2006.01); A61K 31/519 (2006.01); A61K 31/573 (2006.01); A61K 31/675 (2006.01); A61K 31/704 (2006.01); A61K 38/17 (2006.01); A61K 38/50 (2006.01); A61K 40/11 (2025.01); A61K 40/42 (2025.01); A61K 45/06 (2006.01); A61N 5/10 (2006.01); A61P 35/00 (2006.01); C12N 5/0783 (2010.01); A61K 35/12 (2015.01)

CPC C12N 5/0639 (2013.01) [A61K 31/475 (2013.01); A61K 31/519 (2013.01); A61K 31/573 (2013.01); A61K 31/675 (2013.01); A61K 31/704 (2013.01); A61K 38/177 (2013.01); A61K 38/50 (2013.01); A61K 40/11 (2025.01); A61K 40/4211 (2025.01); A61K 40/4221 (2025.01); A61K 40/4224 (2025.01); A61K 40/4234 (2025.01); A61K 45/06 (2013.01); A61N 5/10 (2013.01); A61P 35/00 (2018.01); C12N 5/0636 (2013.01); C12Y 305/01001 (2013.01); A61K 2035/124 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); C12N 2501/2302 (2013.01); C12N 2501/2321 (2013.01); C12N 2510/00 (2013.01)]

15 Claims

1. A composition for treating a canine or a feline animal in need thereof, wherein the composition comprises a modified CD20 antigen specific cell primed by a cell presenting a recombinant CD20 or an antigenic fragment thereof, wherein the composition comprises at least 1.55×10⁵modified CD20 antigen specific cells/kg recipient weight, wherein the modified CD20 antigen specific cell is a propagated T cell.